West Pharmaceutical Services, Inc. · NYSE:WST
West Pharmaceutical Services — Investor Presentation (September 2019)
25 slides from West Pharmaceutical Services's investor presentation, Sep 4, 2019
Slide 1: West Pharmaceutical Services, Inc. September 2019 Investor Presentation
West Pharmaceutical Services, Inc. September 2019 Investor Presentation
Slide 2: Safe Harbor Statement
Safe Harbor Statement Cautionary Statement Under the Private Securities Litigation Reform Act of 1995 This presentation and any accompanying management commentary contain “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements inc
Slide 3: Who We Are – A 95-Year History in Healthcare
Who We Are – A 95-Year History in Healthcare OUR MISSION West contains and delivers injectable therapies that improve patient lives. OUR VISION To be the world leader in the integrated containment and delivery of injectable medicines. 3 WST IR Presentation – September 2019
Slide 4: World Leader in Integrated Containment and Delivery of Injectable Medicines
World Leader in the Integrated Containment and Delivery of Injectable Medicines 41 Billion Annually 112 Million Per Day 5 Million Per Hour 76 Thousand Per Minute 4 WST IR Presentation – September 2019
Slide 5: A Growing Business Well-positioned for Success
A Growing Business Well-positioned for Success 8% 24% 24% >2,000 Customers 34% Net Sales* Largest Customer: Net Sales* 41% Net Sales* 3% By Product By Market ~7% of Total Sales 44% 48% By Geography Category Group 21% 32% 21% >7,700 Employees Americas High-Value Components Pharma Europe, Middle East,
Slide 6: Long-term Growth Strategy
Long-term Growth Strategy Three Core Values 1 3 Market-Led Operational PASSION FOR and Exceptional Effectiveness CUSTOMERS Customer Experience LEADERSHIP IN 2 4 QUALITY Product Shareholder and Service Value Differentiation Creation ONE WEST TEAM 6 WST IR Presentation – September 2019
Slide 7: Our Values: Passion for Customers
Our Values: Passion for Customers Our customers’ success is our success. We innovate to continuously improve our product and service offerings to meet future customer and patient needs. 7 WST IR Presentation – September 2019
Slide 8: Addressing Unique Customer Needs
Addressing Unique Customer Needs Total Cost of Ownership CONTRACT MANUFACTURING PHARMA Life Cycle Management Packaging Solutions for Sensitive Molecules BIOLOGICS Quality & Self-Injection Technologies Design Manufacturing Speed to Market Scalability GENERICS Efficient Manufacturing 8 WST IR Presenta
Slide 9: Addressing Customer Needs with High-Value Products
AddressingWest solutions: Customer Needs with High-Value ProductsIntegrated & containment Services & delivery SELF QUALITY INJECTION BY DESIGN CONTAINMENT CAMERA INSPECTED COATED ADMINISTERED STERILIZED MULTI-COMPONENT ASSEMBLY WASHED ANALYTICAL SERVICES INJECTION MOLDING STANDARD Increasing levels
Slide 10: Integrated Solutions Combine West Offerings in Convenient Packages
Integrated Solutions Combine West Offerings in Convenient Packages Customer Challenges Combination Complex Drug Navigating the Resource Products Development Requirements Constraints Primary Analytical Regulatory & West Packaging Services & Quality & Delivery Technical Support Integrated Systems Supp
Slide 11: Digital Transformation Offers Knowledge and Online Ordering Opportunities
Digital Transformation Offers Knowledge and Online Ordering Opportunities ▪ The West Knowledge Center provides scientific insight and detailed technical information ▪ The West E-Commerce capability offers customers a one-stop solution ▪ WestPharma.com ranks as the highest visited website among key i
Slide 12: Our Values: Leadership in Quality
Our Values: Leadership in Quality 12 WST IR Presentation – September 2019
Slide 13: Operations Footprint Supports Global Customer Base
Operations Footprint Supports Global Customer Base >95 Years >112 Million 27 >3.2 Million < 0.07 OF PROVIDING COMPONENTS MANUFACTURING SQUARE FEET PARTS PER MILLION INNOVATIVE MANUFACTURED FACILITIES AROUND MANUFACTURING OF OUT-OF-SPEC SOLUTIONS DAILY THE WORLD SPACE PARTS 13 WST IR Presentation – S
Slide 14: "One West" Global Operations Management System
“One West” Global Operations Management System Driving Improved Operational Performance One Global Approach Manufacturing Record-Setting Across All Sites Strategy Results in 2018 Procurement Supply Chain Safety Quality Process Excellence Advanced Manufacturing Engineering Service Cost 14 WST IR Pres
Slide 15: Our Values: One West Team
Our Values: One West Team We strive to unleash the talent of each team member at West. Our diverse team of employees spans the globe, but we are united by our integrity and mutual respect for one another, the safety of our work environments, and the communities in which we operate. 15 WST IR Present
Slide 16: Creating a Sustainable Business
Creating a Sustainable Business ▪ Corporate Responsibility Report issued in June 2019 ▪ Six Pillars: • Compliance & Ethics • Philanthropy • Health & Safety • Diversity & Talent • Environmental Sustainability • Quality 16 WST IR Presentation – September 2019
Slide 17: Sustained, Consistent Growth
Sustained, Consistent Growth 250% Constant Adjusted Diluted EPS NYSE: WST Currency CAGR 12.1%* CAGR 6.7% S&P 500 $2.81 200% Reported $1.72 Billion S&P MidCap CAGR 4.8% 400 Index 150% $1.78 100% 50% $1.42 Billion 0% 2013 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 2014 2015 2016 2017 2018 Net S
Slide 18: Second-Quarter 2019 Earnings Highlights
Second-Quarter 2019 Earnings Highlights Reported on July 25, 2019 • Net sales of $469.7 million grew 4.9%, organic sales growth was 8.1% • Reported-diluted EPS of $0.88 increased 17% • Adjusted-diluted EPS of $0.89 increased 27% (1) • Company raised full-year 2019 net sales guidance to a new range o
Slide 19: Becoming a World Leader in Integrated Containment & Delivery of Injectable Medicines
Becoming a World Leader in the Integrated Containment & Delivery of Injectable Medicines ▪ Market-led Strategy ▪ Proprietary Products & Contract Manufacturing Customers Patients ▪ Product & Service VALUE Innovations ▪ Operational Effectiveness Employees Shareholders ▪ Strong Management Team 19 WST I
Slide 20: Slide 20
Slide 21: Notes to Non-U.S. GAAP Financial Measures
Notes to Non-U.S. GAAP Financial Measures For additional details, please see Q2 2019 press release & Safe Harbor Statement ▪ For the purpose of aiding the comparison of our year-over-year results, we may refer to net sales and other financial results excluding the effects of changes in foreign curre
Slide 22: Notes to Non-U.S. GAAP Financial Measures
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures” (Slides 21-25), “Cautionary Statement” (Slide 2) and the Q2 2019 press release for an explanation and reconciliation of these items. Reconciliation
Slide 23: Notes to Non-U.S. GAAP Financial Measures
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures” (Slides 21-25), “Cautionary Statement” (Slide 2) and the Q2 2019 press release for an explanation and reconciliation of these items. Reconciliation
Slide 24: Notes to Non-U.S. GAAP Financial Measures
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures” (Slides 21-25), “Cautionary Statement” (Slide 2) and the Q2 2019 press release for an explanation and reconciliation of these items. Reconciliation
Slide 25: Notes to Non-U.S. GAAP Financial Measures
Notes to Non-U.S. GAAP Financial Measures RECONCILIATION OF NON-U.S. GAAP FINANCIAL MEASURES (UNAUDITED) See “Notes to Non-U.S. GAAP Financial Measures” (Slides 21-25), “Cautionary Statement” (Slide 2) and the Q2 2019 press release for an explanation and reconciliation of these items. Reconciliation
West Pharmaceutical Services — Investor Presentation (September 2019) on 6ix